TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Breyting á fjölda eigin hluta

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Breyting á fjölda eigin hluta

Alvotech announced the European launch of AVT05, its first-in-market biosimilar to Simponi (golimumab), through partner Advanz Pharma. The launch is supported by an NHS England tender award in the United Kingdom. The company also published its financial calendar for 2026.

Insights
FNGS   neutral

Proposed a modular approach to AI agents, focusing on specialized, discrete task performance


ALVO   positive

The company achieved a significant milestone with the European launch of its first-in-market biosimilar, supported by an NHS England tender award, which validates market demand and provides competitive advantage in the biosimilar space.